Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
Rhea-AI Summary
Immunovant (Nasdaq: IMVT) will report financial results for the third quarter ended December 31, 2025 and provide a business update on Friday, February 6, 2026 at 8:00 a.m. ET. Investors can access a conference call (phone registration required) hosted with Roivant (Nasdaq: ROIV) and a live webcast. Presentation materials and a webcast archive will be available in the Investors "News & Events" section of Immunovant's website after the call.
Positive
- None.
Negative
- None.
News Market Reaction – IMVT
In the Jan 26 session, IMVT gained 2.27%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 11 | Equity financing | Negative | +5.3% | Priced $550M common stock offering at $21.00 per share. |
| Nov 10 | Earnings and updates | Neutral | +0.1% | Reported Q2 financials and multi-indication IMVT-1402 clinical updates. |
| Oct 27 | Earnings date notice | Neutral | +2.6% | Announced timing and access details for upcoming Q2 results call. |
| Sep 03 | Clinical data update | Positive | +10.8% | Reported six‑month remission and treatment-free data in Graves’ disease. |
| Aug 11 | Earnings and pipeline | Neutral | -4.5% | Quarterly results with higher R&D and progress on registrational studies. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
IMVT has shown strong positive reactions to clinical data, while financing and routine scheduling or earnings updates have produced mixed and sometimes contrary price moves.
Over the last six months, Immunovant has combined financing, clinical progress, and regular earnings communication. A September 2025 Graves’ disease remission update drove a 10.82% gain, highlighting the market’s focus on clinical durability data. An August and November 2025 earnings cycle emphasized cash runway into a potential 2027 readout, with modest to negative price reactions. A December 2025 $550 million equity financing surprisingly coincided with a 5.31% rise. Prior quarter’s earnings-date scheduling in October saw a 2.57% move, providing a reference for today’s upcoming earnings-timing announcement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026.
To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “News & Events” in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant’s website after the conference call.
About Immunovant
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.
Contacts:
Investors
Keyur Parekh
keyur.parekh@roivant.com
Media
Stephanie Lee
stephanie.lee@roivant.com
